A First-in-Class Drug for Pulmonary Arterial Hypertension

The U.S. Food and Drug Administration (FDA) has approved Winrevair (sotatercept-csrk), an innovative treatment for pulmonary arterial hypertension (PAH) from Merck Sharp & Dohme, under BLA 761363. Winrevair is the first-in-class activin signaling inhibitor, targeting activin, an active protein that inhibits blood vessel growth. Unlike existing treatments that simply dilate blood vessels, this drug restores the balance of cell proliferation and death, directly addressing the underlying cause of the disease, marking a paradigm shift. This approval represents the successful commercialization of a key asset that Merck acquired through its $11.5 billion acquisition of Acceleron Pharma in 2021.

Overwhelming Efficacy Demonstrated Through the STELLAR Phase 3 Trial

The approval is based on the global Phase 3 STELLAR trial, which demonstrated the excellent therapeutic effect of Winrevair when administered in combination with existing background therapy. At week 24 of the treatment, the 6-minute walk distance (6MWD) in patients increased significantly by an average of 41 meters compared to the placebo group, meeting the primary endpoint. Notably, it showed a remarkable secondary result, reducing the risk of clinical worsening or death by 84% compared to the placebo group (Hazard Ratio: 0.16), strongly suggesting the potential for improved survival. Although adverse events such as epistaxis and telangiectasia were observed, it has proven to be a very effective alternative for patients with severe symptoms that are difficult to control with existing standard therapies.

Differentiated Competitiveness Compared to Existing Treatments and Competing Pipelines

The global PAH treatment market is currently led by Uptravi (selexipag) and Opsumit (macitentan) from Johnson & Johnson, and Tyvaso (treprostinil) from United Therapeutics. However, these drugs focus on symptom relief rather than slowing the progression of the disease, resulting in limited efficacy compared to the high treatment costs of tens of millions of won per year. In contrast, Winrevair, as the world's first activin receptor ligand trap, has demonstrated superior combination efficacy and convenience in clinical trials. It not only competes with existing drugs but also has a strong differentiating factor in that it induces vascular remodeling and substantively improves the patient's functional class (WHO Functional Class).

Market Disruption in the $8 Billion Annual Market and a Driver of Revenue Growth

The global PAH market is estimated at approximately $8.0 billion to $8.5 billion and is expected to exceed $12 billion by 2033. Industry experts predict that Winrevair will become a megablockbuster drug, generating annual revenues of up to $3.0 billion shortly after launch. With the patent expiration of its flagship product, Keytruda, in 2028, Merck urgently needed to diversify its portfolio, and this approval has provided a strong growth engine. Ultimately, Winrevair will significantly improve the quality of life for PAH patients with high mortality rates and will play a central role in solidifying Merck's global leadership in the cardiovascular market.